Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance

Vertex Pharmaceuticals IncorporatedTrade
Vanguard Total Stock Market Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Vertex Pharmaceuticals Incorporated vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B), while Vanguard Total Stock Market Index Fund ETF trades at $381.25. Which is the better fit depends on your goals.

VRTXVTI
Market Cap
$132.79B
Sector
Health
52-Week High
$529.65$381.78
52-Week Low
$376.62$311.68
Enterprise Value
$126.92B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.

Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.

Vanguard Total Stock Market Index Fund ETF

VTI trades at $381.78, up 0.71% with strong bullish momentum indicated by moving averages. The ETF shows institutional accumulation with multiple firms increasing positions in Q2 2026. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while ADX confirms strong trend strength. Recent news highlights VTI's role as a core portfolio holding for long-term investors seeking broad market exposure.

VTI offers diversified US equity exposure with low-cost structure, though recent fee competition from competitors like BBUS presents margin pressure. The ETF's 14.53% 10-year annualized return demonstrates strong historical performance. Key risks include market concentration in large-cap tech and broader economic sensitivity. Analyst sentiment remains positive for long-term investors seeking total market diversification.

Returns comparison

Trailing returns across standard periods

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX

About Vanguard Total Stock Market Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.

Read more on VTI